Therapeutic Potential of GLP-1 Receptor Agonists for Smoking Cessation
Glucagon-like peptide-1 (GLP-1) therapies are under investigation for a growing number of neuropsychiatric conditions, including substance use disorders. Cigarette smoking accounts for the largest proportion of substance use-related morbidity and mortality, in part reflecting increased risk for cardiometabolic disease among people who smoke. Given modest quit rates with approved smoking cessation therapies, medications with novel mechanisms of action are needed to expand the available monotherapy and combination treatment options.
How sports betting apps hook users
For most of the last 80 years, sports betting was limited to Las Vegas. But after a 2018 Supreme Court decision loosened regulations on professional sports wagers, it became possible to place bets on games 24/7 — with nothing more than a smartphone and a bank account.
In 2013, just five years prior to the landmark SCOTUS case, gambling was classified in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in a new category called “Substance-Related and Addictive Disorders.” This grouped gambling with alcohol use disorder and other addictions. Gambling is also known to have the highest suicide rate of any addiction.
The Most Effective OCD Treatment Reaches Almost No One: Here’s What We Can Do About It
– Rebecca Deusser, MS, MBA and Sanjaya Saxena, MD
“It took me years to find out that what I was dealing with was OCD!”
This is a phrase all too often repeated by people living with obsessive compulsive disorder. Currently, individuals live with OCD for an average of 7 years (Dell’Osso et al, 2019) before they even receive a diagnosis, all while symptoms may intensify and daily life often becomes increasingly constrained.
Clinicians, researchers, and advocates have long raised this concern. What has been missing is clear data behind how many people with OCD in the U.S. are missed in clinical settings or are not receiving the most effective treatment.
When the International OCD Foundation undertook this analysis, the scale of the problem became unmistakable. Millions of people in America are currently struggling with OCD without the most effective treatment.
The challenges we detail in our new white paper, America’s OCD Care Crisis: National Findings on the Failure of Effective OCD Treatment to Reach Patients, are significant, but fixable. They are symptoms of structural oversights that can be changed. Effective, evidence-based treatment for OCD exists, and through intentional action, we can dramatically change these unacceptable outcomes for people with OCD.
Where People With OCD Fall Through the Cracks
Well established prevalence rates for OCD indicate that nearly 10 million people in America — roughly 3% (Ruscio et al, 2010; Stein et al,2025; Ringeisen et al, 2025) — will have OCD at some point in their lives. Yet our findings suggest that 75% of them are never even identified, and up to 95% aren’t receiving the most effective treatment for the disorder.
In our analysis, we discovered significant systemic breakdowns at several key points of a patient’s journey: screening, diagnosis, referral, and treatment.
- Screening and Diagnosis: Receiving a clinical diagnosis is an important step toward recovery as it promotes understanding and opens paths to effective treatment. Yet our findings suggest that this crucial initial step is missing for many millions of people. Of the 10.4 million patient records reviewed in our analysis, only 0.51% received a formal OCD diagnosis, far below the 3% expected prevalence rate.
- Referral to appropriate care: After a diagnosis is obtained, a handoff to appropriate care is needed to keep the patient from falling out of the treatment pathway. Here, too, we found an alarming gap within our sample: more than 72% of patients identified as having OCD did not receive a referral for cognitive-behavioral therapy (CBT), the most effective treatment for OCD.
- Effective Treatment: Decades of research has established Exposure and Response Prevention (ERP) therapy, a specific form of CBT, as the most effective, first-line therapy for OCD. Yet, an astounding 95-98% of people with OCD had not received ERP treatment. Even when people seek help — and even when they are diagnosed — the vast majority never reach the treatment most likely to help them recover.
What We Can Do About It
The breakdowns seen in each step of the care pathway reinforce the focus of IOCDF’s Vision 2030, our five-year strategy to address the systemic barriers that keep effective OCD treatment out of reach.
While the findings are stark, they illuminate many opportunities for change:
- Identify symptoms earlier by implementing routine OCD screening in primary healthcare and mental health settings.
- Support clinicians in better understanding and treating OCD by expanding training in assessment, diagnosis, and evidence-based treatment modalities.
- Help people receive care that works by strengthening adherence to existing professional treatment guidelines.
- Increase the number of people with OCD who receive effective treatment by supporting affordable access to ERP and other evidence-based therapies.
- Let people know they’re not alone by raising accurate public awareness of what OCD really is — and that it is treatable.
Vision 2030 outlines how the IOCDF is committing its resources, partnerships, and expertise toward advancing these priorities — by increasing awareness and community, expanding access to effective treatment, and advancing research. Together, these efforts are designed to work in concert, improving clinical training, implementing screening for early identification, strengthening pathways from diagnosis to care, and increasing the likelihood that people receive evidence-based treatment.
At the same time, the scale of the problem revealed in this report makes clear that progress depends on collective action across the field. Clinicians, health systems, educators, researchers, policymakers, advocates, and people with lived experience all have a role to play. Together, these efforts can help ensure that people with OCD reach effective treatment sooner, reducing years of unnecessary confusion and distress.
How You Can Help
Join us in building better access to effective treatment for people with OCD:
- Become a member of our grassroots advocacy community.
- Share America’s OCD Care Crisis and other IOCDF resources with your clinicians and healthcare professionals.
- Donate to the IOCDF to support training programs, advance research, and raise awareness of OCD and related disorders.
The current state of treatment for OCD in the U.S. is sobering, but it is not the end of the story. OCD is treatable, recovery is possible, and change can happen as awareness grows and access expands. With continued effort, the gap between how many are struggling and how many receive effective care can begin to close. A brighter future is possible — and we can build it together.
References
- Dell’Osso, B., Benatti, B., Grancini, B., Vismara, M., De Carlo, V., Cirnigliaro, G., Albert, U., & Viganò, C. (2019). Investigating duration of illness and duration of untreated illness in obsessive compulsive disorder reveals patients remain at length pharmacologically untreated. International Journal of Psychiatry in Clinical Practice, 23(4), 311–313. https://doi.org/10.1080/13651501.2019.1621348
- Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 15(1), 53-63. https://doi.org/10.1038/mp.2008.94
- Stein, D. J., Ruscio, A. M., Altwaijri, Y., Chiu, W. T., Sampson, N. A., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Chardoul, S., Gureje, O., Hu, C., Karam, E. G., McGrath, J. J., Navarro-Mateu, F., Scott, K. M., Stagnaro, J. C., Torres, Y., Vladescu, C., Wciórka, J., Xavier, M., … Kessler, R. C. (2025). Obsessive-compulsive disorder in the World Mental Health surveys. Research Square, rs.3.rs-6090427. https://doi.org/10.21203/rs.3.rs-6090427/v1
- Ringeisen, H., Edlund, M., Guyer, H., Dever, J., Carpenter, L., Olfson, M., First, M., Geiger, P., Liao, D., Peytchev, A., Carr, C., Chwastiak, L., Dixon, L. B., Monroe-Devita, M., Scott Stroup, T., Swanson, J., Swartz, M., Gibbons, R., Stambaugh, L., Bareis, N., … Mental Health and Substance Use Disorders Prevalence Study Consortium (2025). Prevalence of past-year mental and substance use disorders, 2021-2022. Psychiatric Services (Washington, D.C.), 76(8), 720–728. https://doi.org/10.1176/appi.ps.20240329
IOCDF Training & Resources for Clinicians
When clinicians have easier access to best practices in OCD diagnosis and treatment, more people can receive effective care. The IOCDF’s Training Institute offers evidence-based programs for clinicians at every stage of practice, including:
- A robust, on-demand webinar catalog (CE-eligible!) covering fundamentals, modalities, related disorders, and comorbidities. The catalog includes access to the free webinar, OCD Basics.
- IOCDF’s Training Institute offers intensive workshops and events, consultation groups, and more for clinicians of every level.
- Professional Members at the IOCDF join a nationwide network of committed professionals, are eligible for listing on our Resource Directory, and have access to special pricing for Training Institute offerings.
The post The Most Effective OCD Treatment Reaches Almost No One: Here’s What We Can Do About It appeared first on International OCD Foundation.
Social cognitive deficits and altered multi-brain dynamics during problem-solving in heroin abstainers: An fNIRS hyperscanning study
Despite extensive research on the neurobiology of addiction, little is known about how repeated drug use and withdrawal are related to social functioning impairments in humans, a highly social species. This obscures the broader societal impact of drug addiction and limits treatment efficacy. This study examined social cognitive impairment and its multi-brain neural underpinnings during socially interactive problem-solving in heroin use disorder (HUD), and further explored their co-occurrence with protracted withdrawal symptoms.
IOCDF Calls for Reinstatement of SAMHSA Grants, Renewed Commitment to Mental Health Support
The International OCD Foundation is alarmed by the apparent sudden and widespread termination of grants supporting vital mental health and addiction services previously funded through the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
These programs provide life-saving services for individuals experiencing acute mental health crises and help prevent symptoms from escalating to emergency or inpatient levels of care.
As detailed in our recent white paper, America’s OCD Care Crisis, 95% of Americans with obsessive compulsive disorder (OCD) are not receiving the most effective treatment. When OCD goes untreated or is treated with approaches that are not evidence-based, individuals face increased distress, functional impairment, isolation, and elevated risk of crisis. Access to trained clinicians and community-based mental health services is essential for helping people remain safe during periods of heightened distress and navigate next steps for treatment.
At a time when so many people with OCD and related disorders already struggle to access appropriate care, reducing support for frontline mental health professionals further weakens an already fragile system.
The IOCDF urges the reinstatement of these grants and continued federal commitment to accessible, evidence-based mental health and addiction services for all who need them.
Contact your congressional representative now to support the reinstatement of SAMHSA grants >>
The post IOCDF Calls for Reinstatement of SAMHSA Grants, Renewed Commitment to Mental Health Support appeared first on International OCD Foundation.
Internet addiction in adolescents with suicidal ideation: the role of self-esteem and school connectedness
Canada Gets its First National Guidance on AI for Mental and Substance Use Health
Ottawa (ONTARIO) – In a first-of-its-kind initiative, national guidance for using artificial intelligence (AI) in the mental and substance use health field is being developed through a partnership between the Canadian Centre on Substance Use and Addiction (CCSA) and the Mental Health Commission of Canada.
AI is increasingly being used for healthcare triage, service navigation, service delivery, and communication, but developers and users have no guidelines specific to mental or substance use health to support its effective and safe use. The recently published E-Mental Health Strategy for Canada highlights the need for safety in this field.
The new National Guidance for Artificial Intelligence Use in Mental Health and Substance Use Health Care will provide guidance, tools, and resources to help practitioners, organizations, and health leaders in efficiently evaluating and implementing AI-enabled mental health and substance use health care services and solutions. It will also support people with lived or living experience of mental health or substance use health concerns in making informed choices about these technologies, while helping technology companies design and improve such solutions to meet the needs of those who use them.
“People are excited about what AI can bring, but the saying ‘break it then fix it’ can take on new dangers when what is at risk is people’s lives. This guidance will allow innovators to move fast while working to ensure it’s done safely and in a way that increases impact and access,” says CCSA CEO Dr. Alexander Caudarella.
The Mental Health Commission of Canada President and CEO Lili-Anna Pereša adds, “Technology can be a powerful ally in transforming mental health care, but innovation must be matched with responsibility. Communities are the best problem-solvers. By working together with developers, providers, and people with lived experience, we’re creating guidance that ensures AI enhances care safely and meaningfully.”
The National Guidance team will share its early findings at several upcoming conferences, including the World Psychiatric Association’s World Congress of Psychiatry, the Canadian Centre on Substance Use and Addiction’s Issues of Substance conference, and the eMental Health International Collaborative (eMHIC) Congress.
In Canada, mental health and substance use health needs are highly common, yet many people continue to face significant barriers to care, including limited access, stigma, financial costs, and lack of tailored treatment options.
The National Guidance for Artificial Intelligence Use with Mental Health and Substance Use Health is expected to launch in 2026/2027.
-30-
About CCSA:
CCSA was created by Parliament to provide national leadership to address substance use in Canada. A trusted counsel, we provide national guidance to decision makers by harnessing the power of research, curating knowledge and bringing together diverse perspectives. CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of Health Canada.
About The Mental Health Commission of Canada:
The Commission leads the development and dissemination of innovative programs and tools to support the mental health and wellness of people in Canada. Through its unique mandate from the Government of Canada, the Commission supports federal, provincial, and territorial governments as well as organizations in the implementation of sound public policy. The Commission’s current mandate aims to deliver on priority areas identified in the Mental Health Strategy for Canada in alignment with the delivery of its strategic plan.
Media contacts:
Canadian Centre on Substance Use and Addiction
Christine LeBlanc, Senior Strategic Communications Advisor
613-898-6343 | cleblanc@ccsa.ca
Mental Health Commission of Canada
media@mentalhealthcommission.ca
The post Canada Gets its First National Guidance on AI for Mental and Substance Use Health appeared first on Mental Health Commission of Canada.
Development of the Healthy Women Intervention to Increase Women’s Engagement in Medication Treatment for Opioid Use Disorder: Mixed Methods, User-Centered Design Approach
Background: Rates of opioid use disorder (OUD) have increased among women over the past 2 decades. Medication treatment for opioid use disorder (MOUD) is effective but underused. Gender-specific treatments for women have been associated with improved substance use outcomes. However, these treatments have not specifically targeted women’s engagement in MOUD, and the impact of existing gender-specific treatments is restricted by in-person delivery. Objective: The aim of this study was to develop a digital intervention to feasibly deliver gender-specific care that addresses the individualized needs of women with OUD to increase engagement in MOUD. Methods: A mixed methods, user-centered design approach was used to inform the development of a digital intervention. In phase 1, qualitative interviews were conducted with women with lived experience of OUD (n=20) and providers who treat women with OUD (n=8). Interviews were recorded, transcribed, and coded for themes. In addition, a larger sample of treatment providers (n=55) completed an online survey to further inform the content of the digital intervention. Phase 2 consisted of designing, beta-testing (n=5), and refining the intervention. Results: The age of women with lived experience ranged from 21 to 59 (mean 38.5, SD 9.4) years; 63% (5/8) of providers interviewed were female participants. The qualitative interview data from women with lived experience and providers were grouped into 6 thematic categories: 3 treatment-related (1) barriers to treatment, (2) facilitators to successful recovery, and (3) important issues to address in treatment, and 3 technology-related (4) positives of using technology as part of treatment, (5) suggested technology features, and (6) barriers to using technology. Across the treatment-related categories, several themes touched on women-specific factors including family responsibilities, abusive partners, stigma, and motivation for treatment (eg, pregnancy). The technology-related categories provided information for designing the features of the intervention, as well as revealing barriers to technology use, which could be helpful in developing implementation strategies. Provider survey participants were primarily female participants (40/55, 73%), with a mean age of 42.5 (SD 12.5) years. Survey data provided additional information on barriers to treatment and suggested technology features. Based on these data and preliminary work, the intervention was created. Minor edits to content and visual design were made in the beta-testing phase. The final version includes a web-based component with 6 topic modules and a mobile component. Topics in the web-based component are presented through infographics, text, videos, and interactive questions. The mobile component includes daily motivational messages, skills practice activities (2/wk), weekly check-ins, and resources (always available). Conclusions: Important themes and suggested features from women with lived experience and providers were incorporated into a digital intervention for women with OUD. Data on feasibility, satisfaction, and engagement with the intervention are currently being collected in phase 3, a pilot randomized controlled trial.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/6b8c4ff957e61601e8e82fd621767c3d" />
ARIA funding
We’re proud to share that Relatix Bio has applied for funding from the UK’s Advanced Research and Invention Agency (ARIA) under their Trust Everything, Everywhere programme. This initiative explores how trust can be built across the digital and physical worlds, and we believe this conversation must include those whose minds work differently.
Our proposal focuses on one of the most pressing and least understood challenges of the digital age: how people with neurodevelopmental and neurodiverse conditions — including autism, ADHD, schizophrenia, borderline traits, and psychopathy — experience, interact with, and build trust in AI systems. In a world increasingly mediated by algorithms, the ways these systems interpret, respond to, and store our most personal thoughts and data matter profoundly.
Throughout history, individuals living with stigmatised neurocognitive conditions have been marginalised or misrepresented — by institutions, by society, and now, potentially, by AI. Some may over-trust technology that feels neutral or supportive; others may under-trust it due to past harm or bias. We want to ensure that digital systems meet people where they are — building trust rather than eroding it. Protecting privacy, and supporting quality of life, health and wellbeing.
Through our work, Relatix Bio aims to lead the way in ethical and inclusive neuro-AI design: protecting privacy, removing stigma, and defining standards for responsible data handling in the era of AI. Our goal is to make sure that the next generation of AI-driven tools — from chatbots to diagnostics — truly serve everyone, regardless of how their brain is wired.
We know how often in the past things have gone wrong — from chatbots unintentionally encouraging depressive or paranoid thoughts, to credit and gambling platforms optimising for addiction or impulsive behaviour. These systems were built without safeguarding those with neurodevelopmental conditions, who may react differently to AI optimised interactions. Many respond by disengaging digitally, and may be feeling that an AI-driven world is a minefield — because it wasn’t built for them.
Join us in shaping a radically different future where cognitive diversity and digital trust can coexist, and AI tools are built to truly support and facilitate. To learn more about our mission or to collaborate contact our team.

